Crum-Cianflone Nancy F, Won Seunghyun, Lee Rachel, Lalani Tahaniyat, Ganesan Anuradha, Burgess Timothy, Agan Brian K
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States; Scripps Mercy Hospital, San Diego, CA, United States; Naval Medical Center San Diego, San Diego, CA, United States.
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.
Vaccine. 2016 Sep 22;34(41):5040-5046. doi: 10.1016/j.vaccine.2016.06.019. Epub 2016 Aug 28.
Vaccination is the most important preventive strategy against influenza, however post-vaccination antibody responses are often inadequate especially among HIV-infected persons. Vitamin D deficiency has been suggested to adversely influence immune responses and is highly prevalent among HIV-infected adults. Therefore, we evaluated the association between 25-hydroxyvitamin D [25(OH)D] levels and post-influenza vaccination responses.
We conducted a prospective cohort study evaluating the immunogenicity of monovalent influenza A (H1N1) vaccination among both HIV-infected and HIV-uninfected adults (18-50years of age) during the 2009-2010 influenza season. Antibody titers were evaluated at baseline, day 28, and 6months post-vaccination using hemagluttination inhibition assays. Serum 25(OH)D levels were measured at day 28. Univariate and multivariate regression analyses examined the association between 25(OH)D levels [categorized as <20ng/ml (deficiency) vs. ⩾20ng/ml] with the primary outcome of seroconversion. Secondary outcomes included seroprotection; a ⩾4-fold increase in titers; and geometric mean titers post-vaccination. Analyses were repeated using 25(OH)D levels as a continuous variable.
A total of 128 adults [64 HIV-infected (median CD4 count 580cells/mm(3)) and 64 HIV-uninfected] were included. Seroconversion at day 28 post-vaccination was achieved in fewer HIV-infected participants compared with HIV-uninfected participants (56% vs. 74%, p=0.03). Vitamin D deficiency was more prevalent among HIV-infected persons vs. HIV-uninfected persons (25% vs. 17%), although not significantly different (p=0.39). There were no associations found between lower 25(OH)D levels and poorer antibody responses at day 28 or 6months for any of the study outcomes among either HIV-infected or HIV-uninfected adults.
Vitamin D deficiency was common among both HIV-infected and HIV-uninfected adults, but lower levels did not predict antibody responses after H1N1 (2009) influenza vaccination. Low 25(OH)D levels do not explain poorer post-vaccination responses among HIV-infected persons.
接种疫苗是预防流感最重要的策略,然而接种疫苗后的抗体反应往往不足,尤其是在艾滋病毒感染者中。维生素D缺乏被认为会对免疫反应产生不利影响,并且在艾滋病毒感染的成年人中非常普遍。因此,我们评估了25-羟基维生素D[25(OH)D]水平与流感疫苗接种后反应之间的关联。
我们进行了一项前瞻性队列研究,评估2009 - 2010年流感季节期间,艾滋病毒感染和未感染的成年人(18 - 50岁)中单价甲型流感(H1N1)疫苗的免疫原性。在基线、接种后第28天和6个月时,使用血凝抑制试验评估抗体滴度。在第28天测量血清25(OH)D水平。单因素和多因素回归分析研究了25(OH)D水平[分为<20ng/ml(缺乏)与⩾20ng/ml]与血清转化的主要结局之间的关联。次要结局包括血清保护;滴度增加⩾4倍;以及接种疫苗后的几何平均滴度。使用25(OH)D水平作为连续变量重复进行分析。
总共纳入了128名成年人[64名艾滋病毒感染者(CD4计数中位数为580个细胞/mm³)和64名未感染艾滋病毒者]。与未感染艾滋病毒的参与者相比,感染艾滋病毒的参与者在接种疫苗后第28天实现血清转化的人数较少(56%对74%,p = 0.03)。艾滋病毒感染者中维生素D缺乏比未感染艾滋病毒者更普遍(25%对17%),尽管差异不显著(p = 0.39)。在感染艾滋病毒或未感染艾滋病毒的成年人中,对于任何研究结局,在第28天或6个月时,较低的25(OH)D水平与较差的抗体反应之间均未发现关联。
维生素D缺乏在感染艾滋病毒和未感染艾滋病毒的成年人中都很常见,但较低水平并不能预测2009年甲型H1N1流感疫苗接种后的抗体反应。低25(OH)D水平并不能解释艾滋病毒感染者接种疫苗后反应较差的情况。